of Ethics - Middle East Journal of Age and Ageing
complies with the Recommendations for the Conduct,
Reporting, Editing, and Publication of Scholarly Work
in Medical Journals, issued by the International Committee
of Medical Journal Editors (ICMJE Recommendations),
and to the Committee on Publication Ethics (COPE)
code of conduct for editors guidelines:
Recommendations for the Conduct, Reporting, Editing,
and Publication of Scholarly Work in Medical Journals
Code of Conduct
1. Statements, permissions, and signatures
o Designated authors should meet all four criteria for
authorship in the ICMJE Recommendations
o We ask all authors, and all contributors (including
medical writers and editors), to specify their individual
contributions at the end of the text
o ME-JAA will not publish any articles unless we have
the signatures of all authors
o We suggest you use the author statement form (below)
and upload or fax the signed copy with your submission
o In addition, please include written consent of any
cited individual(s) noted in acknowledgments or personal
Conflicts of interest
A conflict of interest exists when professional judgement
concerning a primary interest (such as patients' welfare
or validity of research) may be influenced by a secondary
interest (such as financial gain).
relationships are easily identifiable, but conflicts
can also occur because of personal relationships or
rivalries, academic competition, or intellectual beliefs.
A conflict can be actual or potential, and full disclosure
to the Editor is the safest course. Failure to disclose
conflicts might lead to publication of a statement in
our Department of Error or even to retraction. All submissions
must include disclosure of all relationships that could
be viewed as presenting a potential or actual conflict
may use such information as a basis for editorial decisions,
and will publish such disclosures if they are believed
to be important to readers in judging the manuscript.
Agreements between authors and study sponsors that interfere
with authors' access to all of a study's data, or that
interfere with their ability to analyse and interpret
the data and to prepare and publish manuscripts independently,
may represent conflicts of interest, and should be avoided.
o At the
end of the text, under a subheading "Conflicts
of interest", all authors must disclose any financial
and personal relationships with other people or organisations
that could inappropriately influence (bias) their work.
Examples of financial conflicts include employment,
consultancies, stock ownership, honoraria, paid expert
testimony, patents or patent applications, and travel
grants, all within 3 years of beginning the work submitted.
If there are no conflicts of interest, authors should
authors are required to provide a signed statement of
their conflicts of interest as part of the author statement
o For Comment, Seminars, Reviews, and Series, ME-JAA
will not publish if an author, within the past 3 years,
and with a relevant company or competitor, has any stocks
or shares, equity, a contract of employment, or a named
position on a company board; or has been asked by any
organisation other than ME-JAA to write, be named on,
or to submit the paper.
Role of the funding source
o All sources of funding should be declared as an acknowledgment
at the end of the text
o At the end of the Methods section, under a subheading
"Role of the funding source", authors must
describe the role of the study sponsor(s), if any, in
study design; in the collection, analysis, and interpretation
of data; in the writing of the report; and in the decision
to submit the paper for publication
o If there is no Methods section, the role of the funding
source should be stated as an acknowledgment. If the
funding source had no such involvement, the authors
should so state
o The corresponding author should confirm that he or
she had full access to all the data in the study and
had final responsibility for the decision to submit
Role of medical writer or editor
o If a medical writer or editor was involved in the
creation of your manuscript, we need a signed statement
from the corresponding author to include their name
and information about funding of this person
o This information should be added to the Acknowledgments
and/or Contributors section
o We require signed statements from any medical writers
or editors declaring that they have given permission
to be named as an author, as a contributor, or in the
Patient and other consents
o Appropriate written consents, permissions, and releases
must be obtained where you wish to include any case
details, personal information, and/or images of patients
or other individuals in ME-JAA in order to comply with
all applicable laws and regulations concerning privacy
and/or security of personal information. Studies on
patients or volunteers need approval from an ethics
committee and informed consent from participants. These
should be documented in your paper.
o Since the consent form needs to comply with the relevant
legal requirements of your particular jurisdiction,
we do not provide sample forms; this is your responsibility.
Your affiliated institution should be able to provide
an appropriate form.
o For the purposes of publishing in ME-JAA, a consent,
permission, or release should include, without limitation,
publication in all formats (including print, electronic,
and websites), in sublicensed and reprinted versions
(including translations), and in other works and products.
o To respect your patient's and any other individual's
privacy, please do not send signed forms to ME-JAA.
Please instead complete the patient consent section
of the Author statements while retaining copies of the
signed forms in the event they should be needed.
o If consent, permission, or release is made subject
to any conditions, ME-JAA must be made aware in writing
of all such conditions before publication.
o For more information please visit www.me-jaa.com/submitarticles.htm
All manuscripts must be accompanied by necessary statements.
Each author must read and sign all statements:
1. Authorship statement on criteria and responsibility.
2. Financial disclosure statement.
3. Copyright transfer statement (or the statement of
federal employment, if applicable).
4. Human and animal subject protections.
In addition, the corresponding author must sign:
5. Acknowledgment statement. If necessary, photocopy
this document to distribute to co-authors for their
signatures. Please send all copies to the Editorial
Office at the time you submit your manuscript.
For more information please visit www.me-jaa.com/submitarticles.htm
At the external peer review stage you will need to send
signed copies of the following statements:
o Authors' contributions
o Conflicts of interest statements
o Statements of role, if any, of medical writer or editor
o Acknowledgments-written consent of cited individual
o Personal communications - written consent of cited
o Use of copyright-protected material-signed permission
statements from author and publisher
These statements can be scanned and submitted electronically.
To minimise delays, we strongly
advise that you prepare signed copies of these statements
before you submit your manuscript.
Types of article and manuscript requirements
Please ensure that anything you submit to ME-JAA follows
the guidelines provided for each article type. For instruction
on how to format the text of your paper, including tables,
figures, panels, and references, please see Author
o ME-JAA prioritises reports of original research that
are likely to change clinical practice or thinking about
o We invite submission of all clinical trials, whether
phase 1, 2, 3, or 4. For phase 1 trials, we especially
encourage those of a novel substance for a novel indication,
if there is a strong or unexpected beneficial or adverse
response, or a novel mechanism of action
o We encourage researchers to enrol women and ethnic
groups into clinical trials of all phases, and to plan
to analyse data by gender and by race
o Systematic reviews of randomised trials about diseases
that have a major effect on human health also might
warrant rapid peer review and publication
o Global public-health and health-policy research are
other areas of interest to ME-JAA
o We require the registration of all interventional
trials, whether early or late phase, in a primary register
that participates in WHO's International Clinical Trial
Registry Platform (http://www.who.int/ictrp/network/trds/en/index.html)
We also encourage full public disclosure of the minimum
20-item trial registration dataset at the time of registration
and before recruitment of the first participant. The
registry must be independent of for-profit interest
o Reports of randomised trials must conform to CONSORT
2010 guidelines (http://www.consort-statement.org/consort-statement/overview0/),
and should be submitted with their protocols
o All reports of randomised trials should include a
section entitled Randomisation and masking, within the
Methods section o Cluster-randomised trials must be
reported according to CONSORT extended guidelines (http://www.consort-statement.org/extensions/extensions/).
o Randomised trials that report harms must be described
according to extended CONSORT guidelines
o Studies of diagnostic accuracy must be reported according
to STARD (www.stard-statement.org/)
o Observational studies (cohort, case-control, or cross-sectional
designs) must be reported according to the STROBE statement,
and should be submitted with their protocols
o We encourage the registration of all observational
studies on a WHO-compliant registry o Genetic association
studies must be reported according to STREGA guidelines
o Systematic reviews and meta-analyses must be reported
according to PRISMA guidelines (www.prisma-statement.org/).
o To find reporting guidelines see: www.equator-network.org
Articles should, as relevant:
o Be up to 3000 words with 30 references (the word count
is for the manuscript text only)
o Include an abstract (semistructured summary), with
five paragraphs (Background, Methods, Findings, Interpretation,
and Funding), not exceeding 300 words.
o For randomised trials, the abstract should adhere
to CONSORT extensions: abstracts
o For intervention studies, the abstract should include
the primary outcome expressed as the difference between
groups with a confidence interval on that difference
(absolute differences are more useful than relative
ones). Important secondary outcomes can be included
as long as they are clearly marked as secondary
o Use the SI system of units and the recommended international
non-proprietary name (rINN) for drug names. Ensure that
the dose, route, and frequency of administration of
any drug you mention are correct.
o Use gene names approved by the Human Gene Organisation
Novel gene sequences should be deposited in a public
database (GenBank, EMBL, or DDBJ), and the accession
of microarray papers should include in their submission
the information recommended by the MIAME guidelines
Authors should also submit their experimental details
to one of the publicly available databases: ArrayExpress
or GEO (www.ncbi.nlm.nih.gov/geo/)
o All accepted Articles should include a link to the
full study protocol published on the authors' institutional
research into context
o The Discussion section should contain a full description
and discussion of the context. Authors are also invited
to either report their own, up-to-date systematic review
or cite a recent systematic review of other trials,
putting their trial into context of the review.
o We will consider clear and interesting Clinical Pictures
and videos submitted with a descriptive paragraph
o Authors must obtain signed informed consent from the
patient if included in visual material (see Patient
This section should include a description of how authors
searched for all the evidence. Authors should also say
how they assessed the quality of that evidence - ie,
how they selected and how they combined the evidence.
Authors should state here what their study adds to the
evidence when their study is added to previous work.
o Authors must obtain signed informed consent from the
patient (see Patient and other consents)
if you have any questions regarding our code of ethics
Lesley Pocock, Ethics Editor,
Following is a summary of
the Ethics requirements for ME-JAA - for full detail
and implications for your submissions also see Author
1. Publication and authorship:
- list of references, financial support;
- no plagiarism, no fraudulent data;
- forbidden to publish same research in more than one
2. Author's responsibilities:
- authors obliged to participate in peer review process;
- all authors have significantly contributed to the
- statement that all data in article are real and authentic;
- all authors are obliged to provide retractions or
corrections of mistakes.
3. Peer review / responsibility for the reviewers:
- Judgments should be objective;
- reviewers should have no conflict of interest with
respect to the research, the authors and/or the research
- reviewers should point out relevant published work
which is not yet cited;
- reviewed articles should be treated confidentially.
4. Editorial responsibilities:
- e.g. editors have complete responsibility and authority
to reject/accept an article;
- editors should have no conflict of interest with respect
to articles they reject/accept;
- only accept a paper when reasonably certain;
- when errors are found, promote publication of correction
- preserve anonymity of reviewers.
5. Publishing ethics issues
- Monitoring/safeguarding publishing ethics by editorial
- Guidelines for retracting articles;
- Maintain the integrity of the academic record;
- Preclude business needs from compromising intellectual
and ethical standards;
- Always be willing to publish corrections, clarifications,
retractions and apologies when needed.
- no plagiarism, no fraudulent data.